A Russian anti-obesity drug has won high praise from the country's leading diabetes doctor.
The president of the Russian Diabetes Association and corresponding member of the Russian Academy of Sciences, Gagik Glastian, praised the local drug Tirlidia.
According to him, the Russian teraceptide is similar in composition to the American source, but it is significantly cheaper. "This situation does not exist in any other country in the world," the expert noted.
Galastian emphasized that access to modern treatment is a key issue: today less than 2% of diabetes patients receive it, despite the significantly higher need. A more reasonable price for Tirlidia, he believes, could expand treatment options for millions of people.